Introduction
============

Glomerulonephritis encompasses a cluster of diseases that have been described as the most common single cause of end stage renal disease (ESRD) in the world ([@b111-btt-2-531]). GN was listed as the cause of ESRD in over 70,000 US patients in 2004 (US [@b115-btt-2-531]). Glomerulonephritis and hypertension together are also the most common causes of chronic kidney diseases (CKD) in developing countries, and GN trails only hypertension and diabetes as a leading cause of CKD in the US, Europe, and Japan. Notably, for every patient with clinical GN, an estimated 5--10 patients have undiagnosed subclinical disease ([@b23-btt-2-531]). It is thus striking that an estimated 26 million Americans, or 13% of the US adult population, and over 50 million individuals worldwide have CKD ([@b33-btt-2-531]; [@b22-btt-2-531]). Chronic GN may underlie pathogenesis of CKD in a significant proportion of this population. CKD not only places patients at risk for the various complications of renal damage, including increased cardiovascular disease and mortality, but it is estimated that each year more than one million CKD patients develop ESRD. Survival with ESRD requires renal replacement therapy with dialysis or transplantation, costly medical interventions not available in many developing countries. Clearly, effective therapy for GN would have significant impact globally on human health and health care financing.

GN is particularly prevalent among renal allograft recipients ([@b19-btt-2-531]; [@b24-btt-2-531]). Glomerular diseases, including diabetes and glomerulonephritis, account for over 70% of patients receiving renal allografts, and in some countries GN alone accounts for up to 50% of patients ([@b19-btt-2-531]). In a recent review of the Australian registry, among 1505 pts with biopsy-proven GN receiving a primary renal transplant between 1988 and 1997, recurrent or de novo GN occurred in 6%--20% of patients. Recurrence was the third most frequent cause of allograft loss at 10 years, after chronic rejection and death with a functioning transplant. Among patients transplanted due to GN, 8.4% lost their allograft to recurrent GN by 10 years ([@b19-btt-2-531]). These patients may particularly benefit from novel targeted therapies, since disease onset can be readily identified and intervention initiated promptly, if not pre-emptively.

Definition of glomerulonephritis
================================

The glomerulonephritides comprise a group of immunologic diseases that damage the renal glomerulus, the filtering unit of the kidney. This network of capillaries, fed and drained by the afferent and efferent arterioles, respectively, filters plasma across the fenestrated endothelium, glomerular basement membrane (GBM) and podocyte slit diaphragms to collect in Bowman's space. Filtrate is dramatically modified as it passes through a series of tubules before delivery to the renal pelvis for excretion. The approximately 2 million glomeruli in normal adult kidneys filter over 150 liters of plasma per day. With this constant exposure and high filtering capacity, it is perhaps not surprising that the glomerulus is susceptible to injury from immune cells and their soluble products.

GN is defined as inflammation and cell proliferation in the glomerulus, although injury typically extends to the renal tubules, interstitium and vasculature. Common clinical findings include hematuria, proteinuria, and/or decreased glomerular filtration rate, detected as elevation in creatinine, often accompanied by hypertension, edema, and disease-specific findings. Immunopathogenesis is generally attributed to autoimmunity (see below), exacerbated by a local renal immune and inflammatory response. Common entities categorized as GN are indicated in [Table 1](#t1-btt-2-531){ref-type="table"}. These include both renal-limited diseases and nephritides that develop as part of a systemic disorder, as well as those that have both renal-limited and systemic forms, such as anti-GBM nephritis and its systemic counterpart, Goodpasture syndrome. [Table 1](#t1-btt-2-531){ref-type="table"} also includes several additional glomerulopathies with presumed immunologic origins but that are considered noninflammatory because they lack prominent cellular proliferation and infiltrates on renal histopathologic examination. These entities are often treated with immunosuppression regimens similar to those used to treat GN and thus are included in this review.

Current therapies for GN comprise a modest list of broadly immunosuppressive agents ([Table 2](#t2-btt-2-531){ref-type="table"}). Efficacy can be striking, as observed with the combination of steroids and cyclophosphamide, and more recently mycophenolate mofetil, for induction and maintenance therapy in lupus nephritis and the ANCA vasculitides. Newer drugs developed initially to abrogate alloimmunity in transplantation have also proven effective in subsets of GN patients refractory to or intolerant of older established drugs. Nonetheless, these interventions support broad, non-specific blockade of the immune and inflammatory networks, demonstrate variable and often unpredictable efficacy, and carry significant toxicities, including infection, cancer, osteoporosis, avascular necrosis, amenorrhea, sterility, and alopecia. Clearly, more specific safer interventions are urgently needed for this diverse group of diseases. It is therefore notable that a variety of promising new approaches to restore specific immune tolerance to autoantigens, using protein-, cellular-, or gene-based therapies, have entered the clinical arena for multiple autoimmune diseases ([@b123-btt-2-531]). Therapy for GN has lagged in this area, in part because the target antigens in most human immune nephritides remain elusive, unlike their experimental counterparts, and in part because little is known about immune regulatory mechanisms controlling nephritogenic lymphocytes. Our goal in this review is to examine in detail two antigens, alpha3 (IV)NC1 collagen and neutral endopeptidase, and two signaling and effector molecules, FcγR and complement, that are judged to be particularly amenable for novel therapeutic intervention in GN in man. The reader is referred to other recent reviews ([@b53-btt-2-531]; [@b41-btt-2-531]) and [Table 3](#t3-btt-2-531){ref-type="table"} for a more comprehensive cataloguing of potential biologic interventions in GN.

Glomerulonephritis: pathogenesis and potential therapeutic targets
==================================================================

Considerable research in this field is focused on understanding the basic biology and pathogenesis of GN. Animal models have been particularly informative, both in highlighting the role of autoimmunity in the development of most GN and in providing in vivo tools with which to dissect the complex cell interactions that perpetuate disease and specific effector mechanisms that mediate tissue injury and inflammation. These models have revealed multiple targets for intervention, with disease specificity determined by the initiating antigen, the specific receptors on responding B and T lymphocytes, the glomerular antigen targeted locally, and the subset of downstream effectors recruited in a particular disease or individual ([Figure 1](#f1-btt-2-531){ref-type="fig"}).

Three of the most extensively studied animal models of nephritis involve antibody interactions with intrinsic glomerular protein. Autoimmune responses to glomerular basement membrane (GBM) alpha3 (IV) collagen and to glomerular epithelial cell (podocyte) membrane antigens can be induced by active immunization of animals with heterologous or autologous kidney extract. Resulting autoantibodies lead to nephritis marked by linear GBM Ig deposits (eg, autoimmune anti-GBM Ig-mediated disease) or disease dominated by granular subepithelial deposits (eg, active Heymann nephritis), respectively. Nonautoimmune nephritis with similar histopathologic characteristics can be induced by passive administration of preformed antigen-reactive antibodies. A third model, mesangioproliferative nephritis, is induced in rats by passive administration of antibodies that recognize a rat mesangial cell phosphatidylinositol-anchored glycoprotein, termed Thy-1 antigen.

These models, as well as the spontaneous murine lupus models, provide considerable insight and are excellent tools with which to study downstream effector pathways. The specific mediators engaged vary by species, strain, and antigen preparation, and collectively effectively model the heterogeneous nephritis phenotypes observed in man ([Table 1](#t1-btt-2-531){ref-type="table"}). Conversely, the models that depend on passive transfer of differentiated effectors or Ig provide minimal insight into the events that initiate and regulate renal-restricted autoimmunity. Also of unclear relevance to spontaneous human disease is the use of potent adjuvant in active immunization models. Elucidation of tolerance mechanisms that regulate nephritogenic autoreactivity will require novel autoreactive lymphocyte receptor transgenic models that target the relevant kidney antigens ([@b98-btt-2-531]; [@b125-btt-2-531]).

Antigen-based approaches
========================

Kidney antigen is an obvious target for achieving specificity in treating GN. Animal models engage a variety of cell-bound or soluble antigens either native to the glomerulus or that deposit on glomerular structures ([Table 4](#t4-btt-2-531){ref-type="table"}). It is likely that similar antigens are involved in human GN, although to date only two classes of antigens have been confirmed in human disease: the noncollagenous (NC1) domains of the alpha 3 and 5 chains of type IV collagen in anti-GBM nephritis, and neutral endopeptidase in the rare but highly informative antenatal membranous nephropathy. These antigens will be considered in turn below, with regard to their therapeutic exploitation.

Anti-GBM GN and Goodpasture syndrome
------------------------------------

The best characterized and until recently only confirmed kidney target in human GN is alpha3 (IV)NC1 collagen. A pathologic autoimmune response to this antigen leads to focal segmental proliferative and necrotizing GN, frequently with crescent formation. This is associated with linear IgG deposition along the GBM, a pathologic hallmark of the disease. Co-involvement of the alveolar basement membrane with resultant pulmonary hemorrhage is termed Goodpasture syndrome (GPS). This restricted organ involvement is directly related to the restricted tissue expression of the target antigen.

Over the past two decades the molecular nature of the specific epitopes targeted by patient autoantibodies has been carefully dissected. The GBM collagen network is composed of heterotrimers of alpha3, alpha4 and alpha5 chains of type IV collagen. Trimers self associate at their NC1 carboxyl termini, forming NC1 hexamers, and at their amino termini, forming a collagen IV network. The epitopes recognized by the high affinity IgG autoantibodies isolated from serum and kidney eluates of GPS patients have been localized to the NC1 domain of the alpha3 (IV) chain ([@b121-btt-2-531]; [@b100-btt-2-531]). These pathogenic epitopes are conformational and partially sequestered within the NC1 hexamer, minimally accessible for autoantibody binding unless hexamer dissociation into dimers or monomers exposes critical hydrophobic residues ([@b29-btt-2-531]; [@b12-btt-2-531]; [@b14-btt-2-531]; [@b13-btt-2-531]). Environmental or genetic influences that facilitate hexamer dissociation may underlie disease susceptibility ([@b122-btt-2-531]; [@b13-btt-2-531]; [@b54-btt-2-531]). Binding to accessible hydrophilic residues by low affinity autoantibodies may also promote pathogenic epitope exposure by inducing conformational changes and stabilizing monomers ([@b15-btt-2-531]). Two immunodominant antibody epitopes recognized by the majority of GPS patient sera have been mapped using chimeric proteins bearing segments of the alpha3 (IV) chain superimposed on a nonimmunoreactive alpha1(IV)NC1 collagen framework ([@b48-btt-2-531]; [@b76-btt-2-531]; [@b15-btt-2-531]). A restricted number of target epitopes is supported by demonstration of a shared idiotype, and thus shared structural determinant, among GPS serum autoantibodies ([@b71-btt-2-531]).

Epitope and antibody characteristics suggest several targets for specific therapy in anti-GBM nephritis. Selective immunoadsorption using affinity columns coated with antigen can rapidly reduce circulating autoantibody titers in active disease. As proof of concept, affinity chromatography using either purified bovine or recombinant human alpha3 (IV)NC1 collagen completely and selectively depletes pathogenic autoantibodies from patient plasma ([@b17-btt-2-531]). Feasibility of this approach in the clinic is further suggested by the success of repetitive immunoadsorption in removing plasma anti-A or anti-B isotype agglutinins in man; when combined with standard anti-rejection immunosuppression, immunoadsorption permits long-term survival of ABO-incompatible kidney allografts ([@b34-btt-2-531]). This approach has an advantage over the current practice of initiating plasmapheresis in acute GPS, in that it does not deplete protective anti-microbial IgG, a major concern in a patient receiving concurrent cyclophosphamide.

Administration of oral or nasal GBM, bovine alpha3 (IV)NC1 dimers or recombinant rat alpha3 (IV)NC1 collagen can prevent induction of anti-GBM nephritis in antigen-immunized rodents ([@b55-btt-2-531]; [@b91-btt-2-531]; [@b90-btt-2-531]). The tolerance mechanisms remain unclear, although downregulation of Th1 T cell responses is implicated. This approach may have particular utility as pre-emptive therapy in a subset of patients in whom onset of antibody production can be anticipated, such as Alport patients undergoing renal transplantation (see below). The consequences of antigen administration in active disease are less clear and require further study to understand the potential for triggering allergic or pathogenic stimulatory signals.

Antigen-based interventions in lupus nephritis, which has been most extensively studied, are instructive. Proposed approaches include neutralization or depletion of antigen-reactive autoantibodies, B cells, or T cells, using infusion of soluble antigen, peptide epitopes, antigen multimers or anti-idiotypic antibodies, either alone or linked to cytotoxins. It is reasoned that autoantigen epitopes recognized by pathogenic B and T cells can delay or reverse disease if administered in a dose and form that can anergize or delete pathogenic cells or induce inhibitory regulatory cells. In this regard, in lupus mice onset of nephritis can be delayed by biweekly subcutaneous administration of sub-nanomolar quantities of nucleosomal histone peptide ([@b59-btt-2-531]) or by intravenous injection of high doses of a synthetic consensus peptide based on unique T-cell stimulatory epitopes expressed within anti-DNA IgG variable regions ([@b46-btt-2-531]). Immunization with peptide epitopes from anti-nucleosomal IgG variable regions has a similar effect ([@b108-btt-2-531]). Tolerance depends in part on induction of antigen-specific regulatory CD4+CD25+ T cells and CD8+ inhibitory T cells that secrete TGF-beta ([@b63-btt-2-531], [@b64-btt-2-531]; [@b45-btt-2-531]; [@b59-btt-2-531]). IL-10+ regulatory T cells induced by nasal histone peptide ([@b124-btt-2-531]) or high dose intravenous ribonucleoprotein peptide ([@b93-btt-2-531]) are reported to provide protection in the (SWRxNZB)F1 and (NZBxNZW)F1 models of lupus nephritis, respectively. Murine lupus nephritis is also delayed by injection of a 21-mer laminin peptide recognized by a subset of pathogenic murine lupus autoantibodies ([@b5-btt-2-531]). The antigen peptide is located within the laminin alpha1 chain expressed in normal adult kidney mesangium and diseased GBM ([@b2-btt-2-531]). In lupus patients, levels of anti-laminin autoantibodies correlate with disease activity and can be effectively removed by peptide-specific immunoadsorption ([@b6-btt-2-531]). In early human trials, lupus nephritic flares were prevented by administration of double stranded DNA tetramers that putatively adsorb and remove anti-DNA IgG and anti-DNA B cells ([@b4-btt-2-531]); phase III clinical trials testing this reagent are ongoing ([@b43-btt-2-531]).

Alport syndrome, alloantibodies and post-transplant anti-GBM GN
---------------------------------------------------------------

Collagen epitopes also may be targeted therapeutically in patients with Alport syndrome who develop ESRD and undergo kidney transplantation. Alport patients develop a hereditary nephritis due to mutations in one of the genes encoding the alpha chains (alpha3, alpha4, or alpha5) of type IV collagen of the GBM ([@b51-btt-2-531]). Ultrastructurally this is manifest as splitting, thickening and thinning of the involved basement membranes. Clinical consequences are related to the tissue distribution of these alpha(IV) chains and include progressive renal failure, sensorineural deafness and/or ocular abnormalities. Because Alport patients lack the corresponding collagen proteins and thus lack the Goodpasture epitopes in their native basement membranes ([@b81-btt-2-531]; [@b68-btt-2-531]), those who undergo renal transplantation typically develop alloantibodies that bind GBM in the allograft but not the native kidneys. Of these, 3%--5% of patients will also develop anti-GBM GN, despite concurrent post-transplant immunosuppression. Although not all alloantibody target epitopes are known, alloantibody reactivity to NC1 domains of all three alpha chains (alpha3, alpha4, or alpha5) is reported ([@b56-btt-2-531]). Anti-alpha3 (IV)NC1 alloantibodies eluted from the failed renal allograft of one patient with autosomal recessive Alport syndrome and post-transplant anti-GBM GN recognized alloepitopes distinct from Goodpasture autoepitopes ([@b118-btt-2-531]). Thus, Alport patients in particular may benefit from targeted therapies, since disease onset can be readily identified and intervention initiated promptly, if not pre-emptively.

Membranous nephropathy
----------------------

Membranous nephropathy (MN) is a common cause of CKD and accounts for approximately 20% of nephrotic syndrome in adult Caucasians ([@b86-btt-2-531]). By 10 years, 20%--40% of patients progress to ESRD. Given this considerable disease burden, novel effective disease-specific therapies are urgently needed. Important insight into disease pathogenesis was gleaned from study of the rat Heymann nephritis models ([@b26-btt-2-531]). Active HN is induced experimentally by immunization with kidney antigen preparations. Immunized rats develop marked proteinuria and glomerular pathology almost indistinguishable from human MN: thickened glomerular capillary basement membranes due to immune deposition exclusively in the subepithelial space. While it was initially believed that the granular deposits resulted from passive deposition of circulating immune complexes, key experiments subsequently revealed that antibody perfusion of isolated rat kidney led to immediate in situ formation of glomerular deposits ([@b25-btt-2-531]; [@b116-btt-2-531]). The target antigens were subsequently identified as megalin, a large membrane glycoprotein, multiligand endocytic receptor and member of the LDL-receptor-superfamily, and the receptor-associated protein, RAP, constitutively expressed on the rat glomerular podocyte foot processes ([@b60-btt-2-531]; [@b99-btt-2-531]; [@b39-btt-2-531]). Circulating pathogenic antibodies traverse the GBM, bind the megalin-RAP protein complex within the podocyte clathrin-coated pits, and shed as immune complexes that attach to the GBM. Additional autoantibodies in serum of rats with Heymann nephritis contribute to disease by binding distinct epitopes in the podocyte membrane including glycolipid and integrins to activate complement and induce proteinuria ([@b109-btt-2-531]).

Elucidation of pathogenesis in Heymann nephritis spurred a search for podocyte targets in human idiopathic MN. Megalin is not a candidate; although it is found in human renal proximal tubules, it has not been detected in human glomeruli or in immune deposits in patients with MN ([@b61-btt-2-531]). Alternative candidates include dipeptidyl-peptidase IV and neutral endopeptidase (NEP), both of which are expressed on human podocytes and implicated in glomerular immune deposition in experimental models ([@b94-btt-2-531]; [@b95-btt-2-531]), as well as unknown podocyte targets. NEP, an approximately 90 Kd membrane-bound ectoenzyme, was recently identified as target antigen in a rare form of antenatal membranous nephropathy ([@b30-btt-2-531]). Affected infants have subepithelial immune deposits and proteinuria at birth. Their mothers are phenotypically normal but genetically deficient in NEP due to truncating mutations in the Membrane MetalloEndopeptidase (*MME*) gene ([@b31-btt-2-531]). During pregnancy, the fetus expresses normal NEP protein, the gene for which is inherited from the father. NEP-deficient mothers become alloimmunized to NEP in the placental syncytiotrophoblast and fetal tissues. Maternal anti-NEP IgG are transported across the placenta to the fetal circulation during the third trimester, cross the fetal GBM to bind NEP-expressing podocytes in developing glomeruli, and form immune complexes similar to those observed in experimental HN.

Therapeutic and diagnostic implications of NEP-induced MN
---------------------------------------------------------

Two immunodominant linear peptide NEP epitopes recognized by serum of alloimmunized mothers have been identified to date ([@b32-btt-2-531]). These epitopes may provide a basis for antigen-based therapies to prevent kidney injury in fetuses at risk. It is proposed that mothers of affected infants be monitored for circulating anti-NEP antibodies during subsequent pregnancies ([@b96-btt-2-531]). Rising titers can be managed either nonspecifically by plasma exchange, or in an antigen-specific manner using repetitive antigen adsorption. It is further proposed that undetected NEP-deficiency in transplant recipients with subsequent NEP alloimmunization may account for some cases of de novo MN in kidney allografts. Alloimmunization may similarly play a role in MN that develops after bone marrow or hematopoietic stem cell transplantation ([@b96-btt-2-531]). The degree to which maternal NEP-deficiency contributes to CKD in the general population is unknown, but likely to be low. However, observations from antenatal MN have rekindled hopes that nephritogenic podocyte antigens responsible for adult-onset MN will be identified, and ultimately provide novel targets for antigen--specific therapy.

IgG Fc gamma receptors (FcγR) and complement as therapeutic targets in GN
=========================================================================

A large number of cellular and soluble mediators and modulators of immunity and inflammation and cell activation are implicated in immune activation, tissue destruction, remodeling and repair in GN ([Fig. 1](#f1-btt-2-531){ref-type="fig"}). Each of these is a potential target for therapeutic intervention ([Table 3](#t3-btt-2-531){ref-type="table"}). The discussion below focuses on two modulators, IgG Fc gamma receptors (FcγR) and complement, that are particularly amenable to therapeutic manipulation and for which a variety of therapeutic modulators are already in preclinical or early clinical trials.

Notably, whereas the discussion below focuses primarily on the role of FcγR and complement as effectors of renal inflammation, both molecules also modulate activation of B cells and follicular dendritic cells and thus have potent effects on humoral autoimmunity. Both cell types express inhibitory FcγRIIB that engages IgG as well as complement receptors type 1 (CR1, or CD35) and type 2 (CR2, CD21) that recognize activated products of C3 and C4 (reviewed in [@b79-btt-2-531], [@b97-btt-2-531]). Thus, manipulation of these receptor-ligand interactions can alter initial lymphocyte tolerance and activation as well as modulate local renal effector mechanisms.

FcγR
----

IgG receptors link IgG or IgG immune complexes to effector cells by binding the CH2 domain of the Ig heavy chain constant, or Fc, region ([@b89-btt-2-531]). FcγR are constitutively expressed on several cell types that contribute to pathogenesis in nephritis, including macrophages, dendritic cells, neutrophils, mast cells, endothelial cells and B cells, but not T lymphocytes ([@b80-btt-2-531]). There is also evidence that FcγR may be cytokine-inducible on parenchymal cells, including human mesangial cells ([@b88-btt-2-531]). Many FcγR-bearing cells co-express two functional classes of FcγR: activating and inhibitory. Most activating receptors, FcγRI, FcγRIII, FcγRIIA and mouse FcγRIV, transmit signals via an adaptor protein, typically the common gamma chain coreceptor, that contains an ITAM (Immunoreceptor Tyrosine-based Activating Motif). FcγRIIIB is unique in being glycosylphosphatidyl inositol-anchored with selective expression on neutrophils and eosinophils. The one inhibitory receptor, FcγRIIB, is a single chain receptor that transmits signals through an ITIM, or inhibitory motif. The balance of signaling from the two types of receptors sets the threshold for cell activation after stimulation by IgG or IgG-immune complexes. B cells express only inhibitory FcγRIIB, which negatively regulates activating signals from the B cell receptor.

Individual FcγR and allelic variants have restricted IgG isotype specificity and different affinities for the IgG isotypes ([@b78-btt-2-531]; [@b77-btt-2-531]). IgG1 binds the inhibitory FcγRIIB and the activating FcγRIII with low affinity, thus favoring inhibition under basal conditions, whereas IgG2a binds three activating FcγR, FcγRI, FcγRIV, and FcγRIII, with varying affinities and binds inhibitory FcγRIIB with low affinity, thus promoting cell activation. Notably, FcγR expression and IgG isotype are regulated by cytokines, and thus both can vary considerably during the course of disease and during therapy. Transforming growth factor-beta, IL-4 and IL-10 downregulate activating FcγR and upregulate inhibitory FcγRIIB on most effector cells, and induce IgG1 and IgG3 isotypes. In contrast, interferon shifts the balance toward activating FcγR and production of IgG2a and IgG2b isotypes. Thus multiple factors determine the outcome of interactions between FcγR and IgG/immune complexes.

FcγR in GN and potential for therapeutic manipulation
-----------------------------------------------------

In human GN there is evidence that FcγR susceptibility alleles predispose to disease. Perhaps most compelling, Aitman and colleagues demonstrated not only that copy number of the FcγRIIIB gene (FCGR3B) varies between individuals, ranging from none to four copies per cell, but that low FCGR3B copy number and particularly absence of FCGR3B is associated with susceptibility to lupus nephritis ([@b3-btt-2-531]; [@b38-btt-2-531]). Increased risk for lupus nephritis is also described with polymorphisms in FcγRIIB, FcγRIIA and FcγRIIIA in a subset of ethnic groups in some studies ([@b102-btt-2-531]).

Multiple observations in rodent experimental nephritis confirm that engagement of activating FcγR promotes nephritis whereas signaling via inhibitory FcγRIIB ameliorates disease. In the nephrotoxic serum nephritis (NSN) model, susceptible animals are administered heterologous antiserum reactive with recipient GBM. Disease onset is accelerated by prior immunization with species-specific IgG. Because antigen (foreign Ig) is planted in the glomerulus in NSN, this model is used primarily to study downstream effector mechanisms that are recruited either by the deposited heterologous IgG or by the autologous anti-foreign-Ig immune response. In the Wistar Kyoto and related rat strains, susceptibility to NSN and macrophage hyperactivity is associated with a polymorphism in the activating FcγR, FcγRIIIB ([@b3-btt-2-531]). In murine NSN, disruption of the gene encoding the common FcγR gamma chain (FcγR-KO) renders activating FcγR nonfunctional and markedly improves survival and prevents severe nephritis. Glomerular IgG and C3 deposits are unchanged in these mice, suggesting that protection involves interruption of events downstream of immune deposition ([@b82-btt-2-531]; [@b117-btt-2-531]). Reciprocal bone marrow transplantation studies in murine accelerated NSN further show that protection depends on loss of FcγR expression on bone marrow-derived cells, presumably leukocytes ([@b110-btt-2-531]). Genetic deficiency of activating FcγR also confers resistance to lupus nephritis in BWF1 mice, despite persistent serum autoantibodies and renal IgG and C3 deposits ([@b21-btt-2-531]).

Mice administered monoclonal antibody to block activating receptor FcγRIV were also protected from NSN ([@b57-btt-2-531]). FcγRIV-expressing macrophages are recruited to glomerular lesions in this model, suggesting that disease is modulated at the site of tissue injury. Protection was not seen with control antibody infusion, by genetic deletion of FcγRIII, or by combined deletion of the FcγRIII and FcγRI activating receptors. At the time of these studies a deletion model of FcγRIV was not yet developed. Administration of high dose intravenous immunoglobulin, or IVIG, the pooled purified IgG fraction, or its Fc portion, also ameliorated nephritis in this model, concurrent with downregulated expression of FcγRIV on kidney-infiltrating leukocytes ([@b57-btt-2-531]). IVIG also upregulated inhibitory FcγRIIB; however, anti-FcγRIV antibody therapy was effective in NSN in FcγRIIB-deficient mice, confirming a key role for FcγRIV in pathogenesis ([@b57-btt-2-531]).

It is notable that the dominant activating FcγR engaged in NSN is model specific. C57BL/6 mice immunized with sheep IgG develop a dominant IgG2b mouse anti-sheep response ([@b57-btt-2-531]). Mouse IgG2b binds both FcγRIV and FcγRIII, but with different affinities. Induction of NSN in mutant C57BL/6 mice rendered genetically deficient in these activating receptors revealed that FcγRIV is the major if not sole activating FcγR involved in pathogenesis in this model ([@b57-btt-2-531]). In contrast, NSN induced in C57BL/6 mice using rabbit nephrotoxic serum is FcγRIII dependent ([@b42-btt-2-531]). Thus, features of the inciting antigen help determine the nature of the subsequent immune response.

In contrast to the proinflammatory role of activating FcγR, the inhibitory receptor FcγRIIB is protective in several models of experimental nephritis. Genetic deletion of FcγRIIB accelerates mortality in murine NSN ([@b57-btt-2-531]), and leads to severe crescentic GN and massive pulmonary hemorrhage in mice immunized with collagen, an induced model of human spontaneous autoimmune GPS ([@b75-btt-2-531]). Deletion of FcγRIIB also leads to spontaneous autoimmunity and nephritis in a strain-dependent manner in susceptible normal backgrounds ([@b11-btt-2-531]). FcγRIIB-deficient C57BL/6 mice develop proteinuria, immune complex deposition nephritis, activated lymphocytes, anti-chromatin autoantibodies, multiorgan inflammation, and early death. Conversely, deletion of FcγRIIB has no discernable phenotypic effect in the 129/B6 hybrid or BALB/c inbred backgrounds ([@b11-btt-2-531]).

Protection afforded by FcγRIIB appears to include effects at the level of both effector cells and B cell tolerance. Amelioration of NSN by high dose IVIG is accompanied by upregulated expression of FcγRIIB on kidney-infiltrating leukocytes ([@b57-btt-2-531]), suggesting a direct effect on glomerular inflammation. In contrast, development of autoantibodies and proteinuria in FcγRIIB-deficient C57BL/6 mice requires loss of FcγRIIB on B cells, not myeloid cells, as revealed by reciprocal bone marrow transfer experiments ([@b11-btt-2-531]). This dual action is consistent with the roles of FcγRIIB in setting activation thresholds for both B cells and myeloid cells.

Conversely, enhancing expression of inhibitory FcγRIIB can restore tolerance and improve lupus nephritis. This approach was effective in three lupus strains, BXSB, NZM and B6.FcγRIIB-KO, subjected to isologous bone marrow transplantation ([@b69-btt-2-531]). Donor bone marrow cells were transduced with vector carrying a DNA construct encoding FcγRIIB. B cell surface expression of FcγRIIB almost doubled in transplanted recipients. This was associated with significantly improved survival, reduced proteinuria, reduced autoantibody levels, reduced B cell activation, and improved nephritis and lung disease in each mouse strain compared to irradiated transplanted control mice that received mock-transduced bone marrow.

FcγRIIB may play a key pathogenic role in systemic lupus erythematosus, and lupus nephritis in particular. Reduced FcγRIIB expression on activated and germinal center B cells is reported in multiple strains of autoimmune mice, including NZB, NOD, BXSB, and MRL. Low FcγRIIB expression has been linked to polymorphisms in the gene promoter ([@b79-btt-2-531]). In human lupus, reduced FcγRIIB expression on activated B cells and inadequate upregulation of FcγRIIB on memory B cells are reported ([@b67-btt-2-531]). These defects in man have been linked to polymorphisms in the FcγRIIB transmembrane domain that impair the ability of FcγRIIB to enter lipid rafts ([@b40-btt-2-531]; [@b62-btt-2-531],).

Modulation of IgG glycosylation in glomerular inflammatory injury
-----------------------------------------------------------------

IgG binding to FcγR requires Ig glycosylation ([@b58-btt-2-531]). Over 30 different carbohydrate moieties covalently attach to the IgG Fc region via an N-linked glycan at asparagine 297. These glycans can have potent effects on IgG effector functions. The addition of the terminal sialic acid residue decreases IgG binding to selected FcγR by 5- to 10-fold. In an experimental model in which an anti-platelet IgG1 mediates cytotoxicity in vivo, enrichment for IgG sialic acid markedly reduces antibody efficacy and minimizes platelet depletion ([@b58-btt-2-531]).

IgG glycosylation is also important for the therapeutic efficacy of IVIG. In an experimental arthritis model, enrichment for sialic acid enhances IVIG efficacy, such that a 10-fold lower IVIG dose yields the same marked clinical improvement as does full dose nonenriched IVIG ([@b58-btt-2-531]). In this arthritis model, the mechanism appears to involve sialic acid-enriched IVIG upregulation of inhibitory FcγRIIB on macrophages. Conversely, enzymatic removal of all carbohydrate residues from IVIG eliminates most of its efficacy ([@b58-btt-2-531]). These observations may explain the requirement for high doses of IVIG to achieve anti-inflammatory effects clinically; terminally sialylated IgG normally comprises only 5% of total serum IgG, and thus of IVIG.

FcγR and IgG-based therapeutic strategies in GN
-----------------------------------------------

FcγR offer attractive targets for therapeutic modulation in nephritis. Potential approaches include blockade of the various activating FcγR using neutralizing monoclonal antibodies or small molecules, and upregulation or activation of inhibitory receptors, either on effector cells in target tissues or on pathogenic autoreactive B cells. IVIG is currently used therapeutically in nephritis primarily as salvage therapy in refractory disease ([@b112-btt-2-531]). Recent advances in our understanding of mechanisms of action of IVIG provide a blueprint for enhancing its efficacy by glyco-engineering antibody preparations and selectively enriching for desired isotypes. Gene therapy combined with isologous bone marrow transplantation, an approach used to enhance FcγRIIB expression in rodents, is feasible in man. Ultimately, a tailored approach in which FcγR-directed therapy takes into account the IgG isotype that dominates a given disease, the type of effector cells engaged, and the disease- or patient-specific FcγR profile has the potential to revolutionize therapy in GN.

Complement and GN
=================

Glomerular complement deposition is common in immune complex mediated glomerular injury. Targeting complement for intervention, however, requires understanding of the complexity and diverse functions of the complement system ([@b44-btt-2-531]). Over 30 proteins are engaged in the three major pathways of complement activation that converge on components C3, C5 and the terminal pathway that generates the C5b-9 membrane attack complex, or MAC: (1) The classical pathway initiated by immune complex recruitment of C1q, C4 and C2; (2) The alternative pathway in which activating surfaces engage C3b and factors B and D; and, (3) The lectin pathway in which activation depends on microbial carbohydrate interaction with mannose-binding ligand. Activation generates: the anaphylatoxins C3a and C5a that engage specific cell membrane receptors, C3aR and C5aR; C3b that associates with immune complexes; and, the C5b-9 membrane attack complex, or MAC, that inserts into cell membranes to induce sublytic or lytic injury. Complement activation is in turn regulated by a cadre of widely distributed soluble (factor H, C4bp) and cell-bound (decay accelerating factor or DAF, membrane cofactor protein or MCP, CR1, CD59, and rodent CR1-related gene/protein y or Crry) complement inhibitors. Local renal production of complement components, constitutive and inducible renal cell expression of complement receptors and regulatory proteins, and accessibility of locally activated complement proteins to circulating or infiltrating receptor-bearing leukocytes influences the nephritis phenotype.

Complement proteins mediate a variety of key functions that promote immunity and inflammation to protect the host from microorganisms. These same functions occasionally induce autoimmunity and organ damage. Complement activation leads to adjacent cell activation, sublytic injury or death, myeloid cell chemotaxis and activation, and enhanced T-dependent humoral responses. The complement system can also dampen inflammation and immunity, by solubilizing, clearing and processing antigen, immune complexes and apoptotic debris, by regulating B cell responses, and by helping to maintain B cell tolerance. Because of these divergent functions, the therapeutic potential of complement inhibitors in nephritis is complex.

This intricacy is reflected in the paradoxical roles of complement in lupus nephritis. A pathogenic role is supported by the presence of C1q and C3 in inflamed glomeruli and correlation of low serum C3 and C4 levels with disease activity. Yet deficiency, not excess, of complement components C1q, C2 or C4 predisposes to SLE. This paradox is due in part to the primarily protective role of the early classical complement pathway. Genetic deficiency of C1q or C4 worsens nephritis and autoimmunity in murine lupus, and leads to spontaneous onset of autoimmune GN in susceptible normal strains ([@b16-btt-2-531]; [@b87-btt-2-531]; [@b20-btt-2-531]; [@b36-btt-2-531]; [@b72-btt-2-531]; [@b83-btt-2-531]).

Conversely, the alternative pathway may contribute to renal damage. Genetic deficiency of factor B or factor D improves lupus nephritis in the MRL/lpr strain ([@b120-btt-2-531]; [@b37-btt-2-531]), suggesting a predominantly pathogenic role for these components. The alternative pathway is also implicated in a subset of patients with membranoproliferative GN, or MPGN, types I and II. Genetic deficiency of the soluble complement regulatory protein, Factor H, leads to continuous complement activation and C3 turnover in vivo. Pigs and mice with this deficiency develop MPGN that is amenable to therapy with anti-C5 monoclonal antibody ([@b49-btt-2-531]; [@b52-btt-2-531]; [@b84-btt-2-531], [@b85-btt-2-531]). A similar pathogenesis is suspected in the subset of patients with MPGN who have deficient factor H activity due either to mutations in Factor H, to anti-factor H autoantibodies, or to C3 nephritic factor (C3NeF), an autoantibody that binds and stabilizes the alternative pathway C3bBb convertase ([@b70-btt-2-531]; [@b35-btt-2-531]; [@b126-btt-2-531]).

Results in murine MRL/lpr lupus using blockade of C3, a common central component of the complement pathways, are inconsistent. Genetic deficiency of C3 worsens nephritis, suggesting a primarily protective role, similar to that proposed for C1q and C4 ([@b103-btt-2-531]). In contrast, administration of the rodent C3 inhibitor Crry (CR1-related gene/protein y), either as a Crry-Ig fusion protein or in the form of transgenic soluble Crry, improves nephritis, consistent with a pathogenic role for C3 ([@b8-btt-2-531], [@b9-btt-2-531]).

The contribution of complement to pathogenicity in murine anti-GBM disease is equally complex. Deficiency of either C3 or C4 protects against nephritis in the heterologous phase of NSN ([@b105-btt-2-531]). Conversely, in the autologous phase of disease or in accelerated NSN, C3 deficient mice develop worse nephritis ([@b104-btt-2-531]). Deficiency of complement regulators CD59, a terminal pathway inhibitor, CD55 (decay accelerating factor, or DAF), a C3 inhibitor, double deficiency of CD59 and CD55, or double deficiency of CD55 and Crry exacerbates nephritis or proteinuria in murine NSN ([@b113-btt-2-531]; [@b66-btt-2-531]; [@b73-btt-2-531]).

These diverse outcomes reflect the diverse roles for complement at multiple checkpoints during the immune response, including modulation of B cell activation, inflammation, and immune complex clearance. Additionally, some of these discrepancies may be the result of gaps in our understanding of complement biology. In this regard, Huber-Lang et al recently proposed a fourth pathway for complement activation that bypasses C3 ([@b50-btt-2-531]). This novel pathway depends on thrombin and tissue factor to independently generate C5 convertase to activate C5 and the terminal pathway. Lung injury induced by airway instillation of IgG immune complexes was equivalent in C3-sufficient and C3-deficient mice. Importantly, severe lung disease was ameliorated in both cases by administering antibody specific for C5a.

Renal injury resulting from the membrane attack complex, MAC or C5b-9, is best characterized in the noninflammatory passive Heymann nephritis model of membranous nephropathy induced in susceptible rat strains by injection of heterologous antiserum. Proteinuria is largely dependent on in situ complement activation triggered by podocyte-bound IgG, leading to insertion of the MAC into the podocyte membrane and subsequent cell activation, sublytic injury and release of soluble mediators ([@b28-btt-2-531], [@b27-btt-2-531]). By analogy, it is proposed that proteinuria in patients with MN is predominantly MAC-dependent, a view supported by demonstration of MAC in patient urine and renal biopsies ([@b101-btt-2-531]). Interindividual and strain-dependent differences in mechanisms of proteinuria are likely, however, because proteinuria develops in active Heymann nephritis induced in the complement C6-deficient PVG/c rat strain ([@b65-btt-2-531]).

Complement therapeutics in GN
-----------------------------

Although as yet no complement-directed therapy has proven efficacy in nephritis, a variety of complement inhibitors are under development or in clinical trials in human autoimmune and inflammatory diseases ([@b74-btt-2-531]; [@b114-btt-2-531]; [@b92-btt-2-531]). Inhibitors being tested include recombinant soluble forms of naturally occurring inhibitors, soluble complement receptor 1 (CR1), small molecule inhibitors of C3, blocking antibodies or single chain Ig Fv fragments against complement components such as C5, inhibitors of serine proteases, and anaphylatoxin analogues to antagonize C3aR or C5aR. Realization that early components of the classical complement pathway have major protective roles in preventing autoimmunity has shifted focus in nephritis to inhibition of the alternative pathway or downstream complement components and local enhancement of complement inhibitors.

Anti-C5 antibody blocks generation of C5a fragment, C5b and the MAC. Anti-C5 Ig ameliorates lupus nephritis in the BWF1 strain and nephrotoxic serum nephritis in factor H-deficient mice ([@b119-btt-2-531], [@b85-btt-2-531]). Prevention of spontaneous MPGN type II by disruption of the C5 gene in factor H-deficient mice suggests that anti-C5 antibody therapy may also be effective in the subset of MPGN patients with aberrant factor H activity ([@b85-btt-2-531]; [@b106-btt-2-531]). The humanized monoclonal antibody to C5, eculizumab (Alexion), was approved by the FDA in early 2007 for use in patients with chronic hemolytic anemia due to paroxysmal nocturnal hemoglobinuria, an acquired genetic deficiency of complement inhibitors ([@b92-btt-2-531]). Eculizumab was well tolerated in patients with MN but a relatively short four month course failed to significantly reduce proteinuria ([@b7-btt-2-531]). The efficacy of anti-C5 antibody therapy in other human glomerular diseases is yet to be established.

Systemically administered inhibitors that bind the C5aR are in preclinical studies. C5aR is expressed on monocytes, neutrophils and cultured human mesangial cells ([@b18-btt-2-531]) and increased in lupus nephritis kidneys ([@b1-btt-2-531]; [@b10-btt-2-531]). Pharmacological C5aR blockade using a small molecule antagonist prevents progressive lupus nephritis in MRL/lpr mice ([@b10-btt-2-531]).

Alternative strategies that target the site of complement activation and tissue injury in vivo are in development. Targeting permits local concentration of inhibitor while avoiding systemic effects that may compromise host defense or important physiological functions of C3 or C5. Efficacy was demonstrated in experimental proteinuria-induced renal tubulointerstitial injury using rat Crry or CD59 linked to a single chain Fv that targeted a rat proximal tubular epithelial cell antigen ([@b47-btt-2-531]). A fusion protein engineered to link complement receptor 2 (CR2), a binding partner for C3 activation fragments, to a soluble form of the membrane complement inhibitor DAF successfully targeted the inhibitor to inflamed kidney in mouse models of lupus nephritis ([@b107-btt-2-531]). Ongoing investigation is dissecting the contributions of locally expressed complement components, receptors and regulatory proteins in experimental and human nephritis. It is anticipated that knowledge of the biology of complement in individual nephritides, throughout the course of disease and during concurrent immunosuppressive therapy, will ultimately permit appropriate therapeutic targeting.

Summary and conclusion
======================

GN is a common cause of renal injury and CKD that continues to rely on non specific immunosuppression for therapeutic intervention. Recent insights into underlying biology and disease pathogenesis in human nephritis combined with advances in the fields of inflammation and autoimmunity bring the promise of new therapies. Notable breakthroughs include the discovery that alloimmunity to a glomerular antigen underlies antenatal membranous nephropathy, that podocytes are key regulators of glomerular filtration, that complement inhibitors are pivotal to pathogenesis in MPGN, and that IgG Fc receptors form a crucial link between antibody deposition and tissue injury. These discoveries provide the basis for novel therapies based on specific antigen or antibody responses or dominant effector cells or molecules engaged in individual nephritides. Future additional insights into cellular immunity, immune tolerance and regulatory networks, effector mechanisms, and genetic and environmental disease susceptibility will extend this armamentarium and provide the foundation for tailored individualized therapy.

GN

:   glomerulonephritis

ESRD

:   end stage renal disease

CKD

:   chronic kidney disease

GBM

:   glomerular basement membrane

NSN

:   nephrotoxic serum nephritis
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![Pathogenesis of glomerulonephritis. Animal models suggest that autoimmunity underlies pathogenesis of most GN. Disease initiation requires loss of tolerance and activation of self-reactive lymphocytes. Activated B and T cells interact to promote autoantibody and cytokine production, immune complex formation, antibody deposition, macrophage and neutrophil recruitment, renal inflammation, and activation of renal endothelial, mesangial, epithelial and tubular cells. Glomerular and tubulointerstitial antigens may be specifically targeted by autoantibodies and self-reactive CD4 and CD8 TCR alpha/beta effector T cells, gamma/delta T cells and NKT cells. Numerous soluble and cellular mediators participate in subsequent tissue inflammation, injury and repair, and modulate local renal immune responses. The predominant cells and molecules engaged vary depending on the etiology and site of glomerular injury.](btt-2-531f1){#f1-btt-2-531}

###### 

Common glomerulonephritides and glomerulopathies with immune origins

  --------------------------------------------------------
  Renal-limited disease
    IgA nephropathy
    Membranoproliferative glomerulonephritis (MPGN)
    Anti-glomerular basement membrane disease
    Pauci-immune glomerulonephritis
  Systemic disease
    Postinfectious glomerulonephritis
    Lupus nephritis
    Henoch-Schonlein purpura (HSP)
    Goodpasture syndrome
    Wegener's granulomatosis
    Microscopic polyangiitis
    Cryoglobulinemia
  Additional glomerulopathies with immune origins
    Membranous Nephropathy
    Subset of focal sclerosing glomerulosclerosis (FSGS)
    Subset of minimal change disease
    Light chain deposition disease
  --------------------------------------------------------

###### 

Current common nonspecific therapies for glomerulo-nephritis

  -----------------------------------
  Glucocorticoids
  Cyclophosphamide
  Azathioprine
  Chlorambucil
  Intravenous immunoglobulin (IVIG)
  Plasma exchange
  Protein A immunoadsorption
  Mycophenolate mofetil
  Cyclosporine
  Tacrolimus
  Rapamycin
  -----------------------------------

###### 

Potential immunotherapy in autoimmunity and glomeru-lonephritis (after [@b41-btt-2-531])

  -------------------------------------------------------------------------------------------------------------------------
  1\. B and T cell signaling and activation thresholds
    Upregulation or stimulation of B cell inhibitory Fc gamma RIIB
    B cell tolerance induction \[oral alpha3 (IV)NC1 collagen, dsDNA tetramers\][a](#tfn1-btt-2-531){ref-type="table-fn"}
    Inhibition of DNA methylation or histone deacetylation[b](#tfn2-btt-2-531){ref-type="table-fn"}
  2\. B and T cell survival, proliferation and differentiation
    Anti-B cell therapy (anti-CD20 and anti-CD19 mAb)
    Blockade of BAFF/BAFF receptor pathway (anti-BAFF mAb; TACI-Ig fusion protein)
    Modulate activating or inhibitory surface receptors (anti-CD22 mAb)
    Anti-T cell subset therapy
    Blockade of costimulator pathways (CTLA4-Ig, anti-CD40L or anti-ICOSL mAb)
    Stimulation of T cell inhibitory pathways PD-1/PD1-L, CTLA4, BTLA
    Modulation of TLR signaling (inhibitory GpG oligodeoxynucleotides)
    Modified antigen presenting cells (dendritic cell therapy)
    Cytokine or anti-cytokine therapy
  3\. Regulatory cell function
    In vivo or ex vivo induction of regulatory T or B cells
    Administration of tolerizing self-antigen-expressing dendritic or stem cells or B lymphocytes
  4\. Effector cell function and inflammation
    Blockade of Ig production
    Inhibition of memory or plasma cell differentiation
    Blockade or adsorption of autoantibody reactivity
    Complement inhibition (anti-C5 mAb, soluble inhibitors, C5aR antagonist)
    Blockade of activating FcgRI, FcgRIII or (mouse) FcgRIV
    Stimulation or upregulation of inhibitory FcgRIIB
    Cryo-engineered, IgG isotype-restricted, or synthetic (pooled designer mAb) IVIG
    Inhibition of secondary mediators (cytokines, chemokines, NO, ROS, lipid mediators, etc)
    Anti-macrophage or neutrophil therapy
    Adhesion molecule blockade (anti-CD11a, anti-ICAM-1)
    T helper subset skewing (rIL-10)
    Cytokine blockade (anti-TNFalpha, TNFR2-Ig, IL-1ra)
  5\. Intrinsic renal cell activation and proliferation
    Blockade of growth factors (PDGF), chemokines, cell cycle proteins
    Upregulation or targeted localization of complement regulatory proteins
    Downregulation or blockade of activating FcgR
  -------------------------------------------------------------------------------------------------------------------------

^a^Selected examples of interventions currently in preclinical or clinical trials are in parentheses.

^b^Some interventions modulate multiple checkpoints; for simplicity, only one category is shown.

**Abbreviations:** TLR, toll-like receptor; PD-1, programmed death-1; CTLA-4 (cytotoxic T lymphocyte antigen-4); BTLA, B and T lymphocyte attenuator.

###### 

Antigen targets in immune-mediated glomerular injury

  Experimental models                  Human
  ------------------------------------ ----------------------------------------
  Basement membrane antigens           Basement membrane antigens
    Collagen, laminin                    Alpha3 (IV)NC1 (GPS, ARAS allograft)
    Heparan sulfate                    
    Proteoglycan, chondroitin A          Alpha5(IV)NC1 (XLAS allograft)
  Intrinsic renal cell antigens        Intrinsic renal cell antigens
    Endothelial cell                     Neutral endopeptidase (antenatal MN)
    Mesangial cell                     
    Podocyte (proteins, glycolipids)   
  Soluble nuclear antigens             
    DNA, histone, nucleosome           
  Soluble immune elements              
    Autologous Ig, C1q                 

**Abbreviations:** GPS, Goodpasture syndrome; ARAS, Autosomal recessive Alport syndrome; XLAS, X-linked Alport syndrome; MN, membranous nephropathy.
